Norisoboldine is primarily studied for its anti-inflammatory and immunomodulatory properties. It has shown potential in the treatment of autoimmune and inflammatory diseases, particularly rheumatoid arthritis. The compound works by inhibiting key signaling pathways such as NF-κB and MAPK, which play central roles in the production of pro-inflammatory cytokines. It also suppresses the activation and proliferation of T cells, helping to reduce immune system overactivity. In addition, norisoboldine has demonstrated protective effects on joint tissues by reducing cartilage degradation and bone erosion in preclinical models. It may also improve gut barrier function and modulate the gut microbiota, suggesting a role in managing inflammatory bowel diseases. Due to its natural origin and multi-target activity, it is being explored as a lead compound for developing new anti-inflammatory agents with fewer side effects.